Drug Landscape ›
Refresh Tears ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 3,620
Most-reported reactions
Drug Ineffective — 797 reports (22.02%) Macular Degeneration — 667 reports (18.43%) Eye Pain — 365 reports (10.08%) Eye Irritation — 359 reports (9.92%) Off Label Use — 284 reports (7.85%) Nausea — 249 reports (6.88%) Headache — 248 reports (6.85%) Pain — 224 reports (6.19%) Cataract — 218 reports (6.02%) Malaise — 209 reports (5.77%)
Source database →
Refresh Tears in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Refresh Tears approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Refresh Tears in United States?
Pharmaceutical Research Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.